AivoCode
Biotechnology startup developing platform technologies for targeted delivery to diseased regions of the central nervous system. The company uses unbiased in vivo screening to identify short homing peptides that selectively accumulate in injured or disease-specific brain and retinal tissue, and applies these ligands to deliver therapeutic peptides, antibody therapeutics, diagnostic probes, and nanoparticle-based payloads. Activities include preclinical development in animal models, peptide optimization, biomarker-driven probe development, and management of government-funded translational programs.
Industries
Nr. of Employees
small (1-50)
Products
Peptide therapeutic candidate for acute traumatic brain injury (preclinical)
A peptide-based therapeutic developed for systemic administration to reduce secondary injury, inflammation, and lesion size in preclinical TBI models.
Panel of homing peptides for targeted CNS and retinal delivery
Short peptide ligands identified by in vivo screening that selectively bind disease- or injury-specific signatures for use in targeted delivery of therapeutics and diagnostics.
Antibody therapeutics targeting early vascular dysfunction in neurodegeneration
Discovery-stage antibody programs focused on vascular targets implicated in early-stage neuroinflammation and vascular dysfunction for neurodegenerative disease intervention.
Peptide-guided nanoparticle delivery platform (preclinical)
Conjugation of homing peptides to nanoparticles to deliver imaging agents, small molecules, and gene-silencing oligonucleotides to injured CNS tissue.
AC01
A first-in-class therapeutic developed for traumatic brain injury (TBI) and neuroinflammation, with potential applications in other indications such as optic neuropathies and glaucoma.
Intravitreal therapeutic for subretinal fibrosis
A first-in-class intravitreal therapeutic designed to inhibit subretinal fibrosis in patients with wet AMD using camelid single domain nanobodies (VHH) that block inflammatory and fibrotic factors.
Peptide therapeutic candidate for acute traumatic brain injury (preclinical)
A peptide-based therapeutic developed for systemic administration to reduce secondary injury, inflammation, and lesion size in preclinical TBI models.
Panel of homing peptides for targeted CNS and retinal delivery
Short peptide ligands identified by in vivo screening that selectively bind disease- or injury-specific signatures for use in targeted delivery of therapeutics and diagnostics.
Antibody therapeutics targeting early vascular dysfunction in neurodegeneration
Discovery-stage antibody programs focused on vascular targets implicated in early-stage neuroinflammation and vascular dysfunction for neurodegenerative disease intervention.
Peptide-guided nanoparticle delivery platform (preclinical)
Conjugation of homing peptides to nanoparticles to deliver imaging agents, small molecules, and gene-silencing oligonucleotides to injured CNS tissue.
AC01
A first-in-class therapeutic developed for traumatic brain injury (TBI) and neuroinflammation, with potential applications in other indications such as optic neuropathies and glaucoma.
Intravitreal therapeutic for subretinal fibrosis
A first-in-class intravitreal therapeutic designed to inhibit subretinal fibrosis in patients with wet AMD using camelid single domain nanobodies (VHH) that block inflammatory and fibrotic factors.
Expertise Areas
- Targeted CNS drug delivery
- Peptide therapeutic discovery and optimization
- Biomarker-driven probe development for neuroinflammation
- Preclinical neuroprotection and TBI models
Key Technologies
- In vivo phage display
- Homing peptide ligands
- Peptide–drug and peptide–nanoparticle conjugation
- siRNA/oligonucleotide delivery via targeted nanoparticles
News & Updates
Company presentation at RESI (conference).
Awarded multi-year DARPA Cornerstone program contract as part of a team to develop preventative interventions to stop traumatic brain injury.
Direct-to-Phase II SBIR award to support development of a peptide therapeutic candidate for traumatic brain injury.
NSF SBIR Phase II project to develop precision-guided delivery of drugs or diagnostics to sites of damage in traumatic brain injury, including peptide optimization and small-molecule mimetic screening.
SBIR Phase I grant from the National Institute on Aging to develop therapies that target vascular deficits as an intervention in Alzheimer's disease.
NIH Phase I SBIR grant from NINDS to support development of therapies for moderate-severe traumatic brain injury.
Company presentation at RESI (conference).
Awarded multi-year DARPA Cornerstone program contract as part of a team to develop preventative interventions to stop traumatic brain injury.
Direct-to-Phase II SBIR award to support development of a peptide therapeutic candidate for traumatic brain injury.
NSF SBIR Phase II project to develop precision-guided delivery of drugs or diagnostics to sites of damage in traumatic brain injury, including peptide optimization and small-molecule mimetic screening.
SBIR Phase I grant from the National Institute on Aging to develop therapies that target vascular deficits as an intervention in Alzheimer's disease.
NIH Phase I SBIR grant from NINDS to support development of therapies for moderate-severe traumatic brain injury.